Human subjects protections policies do not provide regulatory coverage for all clinical trials, while up to about a quarter of trials are considered overlap trials, according to a research letter published in the March 5 issue of the Journal of the American Medical Association.
The human papillomavirus vaccine is effective at protecting against cervical abnormalities in young women, according to a study published March 4 in BMJ.
By Christina Izzo
Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options
The top U.S. internal medicine residency programs have been ranked by physicians and include Massachusetts General Hospital in Boston, Johns Hopkins University in Baltimore, Brigham and Women's Hospital in Boston, and the University of California in San Francisco, according to an article published by U.S. News & World Report.
By Judy C. Boughey, MD, FACS
As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.
For patients with advanced melanoma, nivolumab may improve overall survival and has an acceptable long-term safety profile, according to a study published online March 3 in the Journal of Clinical Oncology.
By Abigail L. Stockham, MD, and Nils D. Arvold, MD
In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.
Postmenopausal women are at higher risk of developing diabetes if they have both a hysterectomy and bilateral oophorectomy, according to a study published in the March issue of Diabetes Care.
By Nick Sambides, Jr.
Set for full rollout on October 1, the much delayed 10th revision of the International Statistical Classification of Diseases and Related Health Problems is probably the biggest revision to medical coding and billing since computerized medical coding and billing practices began decades ago.
By Rachel Lutz
Mice models demonstrating colorectal cancer development were influenced by nongenetic factors such as gut microbes.
Women are still underrepresented in medical science and research, and sex differences are often ignored, according to a report published March 3 by the Brigham and Women's Hospital.
By Jeannette Wick
Although overall mortality related to breast cancer in women is declining, patients with locally advanced breast cancer still pose a challenge to oncologists.
There will be no more delays to the Oct. 1, 2014, deadline for implementation of the International Classification of Diseases, 10th Revision, according to an article published Feb. 27 in Medical Economics.
By Anita T. Shaffer
Eribulin mesylate (Halaven) proved safe and effective as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer in final phase II clinical trial results
By Tony Berberabe, MPH
Bavituximab, Peregrine Pharmaceuticals’ lead clinical immunotherapeutic candidate, received Fast Track designation from the FDA to kick off 2014.
By Ryan C. Fields, MD
As melanoma becomes more prevalent and more lethal in the United States, a multidisciplinary approach for treating inoperable in-transit metastases has proved to be a viable and valuable option.
By Beth Fand Incollingo
An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.
By Jane de Lartigue, PhD
A greater understanding of the molecular mechanisms underlying lymphoid malignancies has fostered the development of targeted therapies, including those aimed at B-cell signaling pathways.
Stethoscopes get contaminated after a single physical exam, with the contamination greater than that seen on most of the physician's dominant hand, barring the fingertips, according to a study published online Feb. 27 in the Mayo Clinic Proceedings.
By Silas Inman
A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.